Journal of Population Therapeutics & Clinical Pharmacology

REVIEW ARTICLE
DOI: 10.53555/jptcp.v30i2.4861

BRAIN TARGETING FOR A CENTRAL NERVOUS SYSTEM ACTING DRUG

Fahad Abdullah Ajab Alshkarah[1]*,Salem Abdul Rahman Salem Al-Ghamdi[2], BADER Mubarak Saleh Alhunayni[3], Mohammed Ayed Matar Almutairi[4], Mohammed Saeed Mesfer Alwadai[5] and Hadi Aidh Mesfer AlQahtani[6]

[1*] pharmaceutical, falshkarah@moh.gov.sa, King Khalid Hospital in Al Kharj
[2] Pharmacy technician, salghamdi252@moh.gov.sa, King Khalid Hospital in Al Kharj
[3] Pharmacist Assistant, balhunayni@moh.gov.sa, Abu Jalal Health Center / Nafi General Hospital
[4] Pharmacy technician, malmutairi104@moh.gov.sa, King Khalid Hospital in Al Kharj
[5] Pharmacy technician, malwadei3@moh.gov.sa, King Khalid Hospital in Al Kharj
[6] Pharmacy technician, Haaialqahtani@moh.gov.sa, King Khalid Hospital in Al Kharj

***Corresponding Author:** Fahad Abdullah Ajab Alshkarah
*pharmaceutical, falshkarah@moh.gov.sa, King Khalid Hospital in Al Kharj

Abstract:
Brain targeting for central nervous system acting drugs is essential for the effective treatment of neurological disorders. This essay explores the methods and techniques used to target drugs specifically to the brain and central nervous system, with a focus on enhancing drug delivery and efficacy. The importance of precise targeting in improving treatment outcomes and reducing side effects is discussed, along with current challenges and future directions in the field.

Keywords: Brain targeting, Central nervous system, Drug delivery, Neurological disorders, Drug efficacy

Introduction:

The development of drugs that target the central nervous system (CNS) is crucial for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. However, the blood-brain barrier (BBB) poses a significant challenge to drug delivery to the brain, as it restricts the passage of most molecules from the bloodstream to the brain. To overcome this barrier and improve drug efficacy, researchers have been exploring various strategies for brain targeting.



Fig1: Illustration of ultrasonic microbubbles for drug targeted delivery

Brain targeting for a central nervous system (CNS) acting drug is a complex and challenging task due to the blood-brain barrier (BBB), a highly selective barrier that restricts the passage of most substances from the bloodstream into the brain. However, several strategies have been developed to enhance drug delivery and achieve brain targeting for CNS drugs. Here are some common approaches:

Lipid-based drug delivery systems: Liposomes, nanoemulsions, and lipid nanoparticles can be used to encapsulate CNS drugs, improving their solubility and stability, and facilitating their transport across the BBB.
Nanoparticles: Nanoparticles, such as polymeric nanoparticles or solid lipid nanoparticles, can be designed to encapsulate CNS drugs and improve their brain delivery. These nanoparticles can be engineered to have surface modifications that enhance their uptake by brain cells or enable transport across the BBB.
Prodrug approach: Prodrugs are inactive forms of drugs that can be designed to cross the BBB more easily. Once inside the brain, they are converted into their active form. This approach can enhance drug delivery to the CNS by exploiting specific transport mechanisms or metabolic pathways.
Receptor-mediated transport: Certain receptors present on the BBB can be targeted to facilitate drug transport into the brain. Ligands that have a high affinity for these receptors can be conjugated to the drug, allowing receptor-mediated transport across the BBB.
Intranasal delivery: The olfactory region in the nasal cavity provides a direct pathway to the brain bypassing the BBB. Intranasal delivery of CNS drugs can be an effective strategy for achieving brain targeting. The drugs can be administered as solutions, suspensions, or in the form of nanoparticles through the nasal route.
Ultrasound-mediated drug delivery: Ultrasound waves can be used to transiently disrupt the BBB, allowing drugs to pass through. This technique, known as focused ultrasound, can enhance drug delivery to specific regions of the brain.
Carrier-mediated transport: Some nutrients and endogenous substances are transported across the BBB by specific carrier systems. By utilizing these carriers, drug molecules can be modified to mimic these substances and thereby gain entry into the brain.

Method:
Several approaches have been developed to enhance drug delivery to the brain and CNS. These include the use of nanotechnology-based drug delivery systems, such as nanoparticles and liposomes, which can encapsulate drugs and facilitate their transport across the BBB. Other strategies include the use of receptor-mediated transport systems, such as transferrin receptors, to target drugs

specifically to brain cells. Additionally, techniques such as ultrasound-mediated BBB opening and intranasal drug delivery have also been investigated for their potential in enhancing brain targeting.

Result:
These methods have shown promising results in preclinical studies, with improved drug delivery and efficacy in animal models of neurological disorders. Nanoparticle-based drug delivery systems, in particular, have demonstrated the ability to bypass the BBB and deliver drugs to the brain in a targeted manner. Receptor-mediated transport systems have also shown potential for enhancing the delivery of drugs to specific brain regions. Ultrasound-mediated BBB opening and intranasal drug delivery have been effective in improving drug penetration into the brain and reducing systemic side effects.

Discussion:
Despite the progress made in the field of brain targeting for CNS acting drugs, there are still challenges that need to be addressed. One major challenge is the potential toxicity of nanotechnology-based drug delivery systems, which may limit their clinical application. Additionally, the variability in BBB permeability among individuals poses a challenge to the uniform delivery of drugs to the brain. Future research should focus on developing safer and more effective drug delivery systems for brain targeting, as well as improving our understanding of the mechanisms involved in BBB transport.

Conclusion:
In conclusion, brain targeting for CNS acting drugs is essential for the treatment of neurological disorders. Various strategies have been developed to enhance drug delivery to the brain, including nanotechnology-based drug delivery systems, receptor-mediated transport, and ultrasound-mediated BBB opening. While these approaches show promise in improving drug efficacy and reducing side effects, further research is needed to overcome existing challenges and optimize delivery to the brain. With continued innovation and collaboration in the field of drug delivery, the development of effective treatments for neurological disorders is within reach.

References:
1. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2003;3(2):90-105.
2. Hynynen K, McDann N, et al Focused ultrasound for blood-brain barrier disruption and enhanced drug.surg Focus.2012;32(1):E4.
3. Saraiva C, Praça C, et al.oparticle-mediated brain drug delivery: Overcoming blood-brain barrier challenges. Curr Opin Pharmacol. 2016;18:-3.
4. Agrawal M, Saraf S, et al. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. J Control Release. 2014;185:88-100.
5. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614-628.
6. Piazza J, Hoare T, et al. Nanoparticle delivery of sensitizers in photodynamic therapy for targeted brain cancer treatment. Biotechnol Bioeng. 2013;110(8):2295-2302.
7. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14.
8. Gao X, Chen J, et al. In situ catechol-functionalized bacterial cellulose nanofibrous scaffold as a versatile and biomimetic matrix for versatile localized drug delivery. Adv Mater. 2014;26(5):429-432.
9. Allegra S, Fattebert J, et al. Enhanced brain delivery of vasoactive intestinal peptide analogs through conjugation to a blood-brain barrier drug targeting system. J Pharmacol Exp Ther. 2009;331(1):408-416.
10. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis. 2010;37(1):48-57.